Search results
MDMA Therapy For PTSD Closer To Legality As Key FDA Approval Meeting Approaches, Sparking Hope And...
Benzinga· 2 days agoMDMA, the drug commonly known as ecstasy and declared illegal by the DEA in 1985, is nearing a landmark moment in its journey toward becoming a legal and approved ...
Panel rejects psychedelic drug MDMA as a PTSD treatment in possible setback for advocates
San Francisco Chronicle· 8 hours agoA first-of-a-kind proposal to begin using the mind-altering drug MDMA as a treatment for PTSD was...
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type...
Morningstar· 5 days agoRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has extended by three months the target action date of ...
Guest column: With FDA approval of software treatment for depression, the digital medicine...
WRAL TechWire· 5 days agoIn a watershed moment for digital health innovation, the FDA recently granted clearance to Rejoyn, a...
Landmark review spotlights challenge of judging psychedelic therapies
Axios· 2 days agoThe challenges of mainstreaming psychedelic therapies for conditions like PTSD, anxiety and major depression will be brought home this week when federal drug advisers scrutinize what could be ...
RYBREVANT® (amivantamab-vmjw) plus lazertinib is the only chemotherapy-free regimen showing longer...
Morningstar· 5 days agoInvestigational chemotherapy-free regimen of RYBREVANT® plus lazertinib addresses a significant unmet need as most patients with EGFR-mutated NSCLC have high-risk disease Landmark< ...
Landmark Blood-Based AI Lung Cancer Screening Test Study Results Published in Cancer Discovery
Tehachapi News· 2 days agoThe transformative approach to genomic sequencing yields the first validated high-sensitivity lung cancer screening test that could close gaps in screening. BALTIMORE and PALO ALTO, Calif., ...
'Outstanding' 5 Year PFS With Lorlatinib in ALK+ NSCLC
Medscape· 4 days agoFive-year follow-up data from the landmark CROWN trial shows significant progression-free survival in ALK+ NCSLC, but some experts question the use of crizotinib as the comparator drug.
ComboMATCH Precision Medicine Cancer Trials
National Cancer Institute· 16 hours agoComboMATCH (Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice) is a group of precision medicine cancer clinical trials,...
Here’s what to expect as the Supreme Court enters the final stretch | CNN Politics
CNN.com· 3 days agoThe Supreme Court is turning toward the final, frenzied weeks of its term, readying potential...